Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 189

1.

Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?

Gajic-Veljanoski O, Bayoumi AM, Tomlinson G, Khan K, Cheung AM.

Osteoporos Int. 2012 Nov;23(11):2681-92. doi: 10.1007/s00198-012-1939-4. Epub 2012 Mar 8.

PMID:
22398856
[PubMed - indexed for MEDLINE]
2.

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.

Health Technol Assess. 2005 Jun;9(22):1-160. Review.

PMID:
15929857
[PubMed - indexed for MEDLINE]
Free Article
3.

Vitamin K to prevent fractures in older women: systematic review and economic evaluation.

Stevenson M, Lloyd-Jones M, Papaioannou D.

Health Technol Assess. 2009 Sep;13(45):iii-xi, 1-134. doi: 10.3310/hta13450. Review.

PMID:
19818211
[PubMed - indexed for MEDLINE]
Free Article
4.

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.

Pharmacoeconomics. 2008;26(4):311-28.

PMID:
18370566
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Nayak S, Roberts MS, Greenspan SL.

Ann Intern Med. 2011 Dec 6;155(11):751-61. doi: 10.7326/0003-4819-155-11-201112060-00007.

PMID:
22147714
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.

Ström O, Jönsson B, Kanis JA.

Osteoporos Int. 2013 Apr;24(4):1491-502. doi: 10.1007/s00198-012-2115-6. Epub 2012 Dec 7.

PMID:
23224141
[PubMed - indexed for MEDLINE]
7.

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA.

Osteoporos Int. 2010 Feb;21(2):339-49. doi: 10.1007/s00198-009-0971-5. Epub 2009 Jun 10.

PMID:
19513577
[PubMed - indexed for MEDLINE]
8.

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

Jansen JP, Gaugris S, Bergman G, Sen SS.

Curr Med Res Opin. 2008 Mar;24(3):671-84. doi: 10.1185/030079908X260998. Epub 2008 Jan 24.

PMID:
18221588
[PubMed - indexed for MEDLINE]
9.

The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.

Stevenson M, Davis S, Lloyd-Jones M, Beverley C.

Health Technol Assess. 2007 Feb;11(4):1-134. Review.

PMID:
17280622
[PubMed - indexed for MEDLINE]
Free Article
10.

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

Borgström F, Ström O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA.

Osteoporos Int. 2010 Mar;21(3):495-505. doi: 10.1007/s00198-009-0989-8. Epub 2009 Jun 30.

PMID:
19565175
[PubMed - indexed for MEDLINE]
11.

Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.

Hiligsmann M, Ben Sedrine W, Bruyère O, Reginster JY.

Osteoporos Int. 2013 Aug;24(8):2291-300. doi: 10.1007/s00198-013-2272-2. Epub 2013 Feb 1.

PMID:
23371359
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.

Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12.

PMID:
24231131
[PubMed - indexed for MEDLINE]
13.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
[PubMed - indexed for MEDLINE]
14.

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.

Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA.

Osteoporos Int. 2014 Jan;25(1):325-37. doi: 10.1007/s00198-013-2521-4. Epub 2013 Oct 10.

PMID:
24114398
[PubMed - indexed for MEDLINE]
15.

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.

Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y.

Value Health. 2012 Jan-Feb;15(1 Suppl):S20-8. doi: 10.1016/j.jval.2011.11.015.

PMID:
22265062
[PubMed - indexed for MEDLINE]
16.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann M, Reginster JY.

Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009. Epub 2010 Mar 18.

PMID:
20303422
[PubMed - indexed for MEDLINE]
17.

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study.

Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, Chlebowski RT, Manson JE, Van Horn L, Vitolins MZ, Datta M, LeBlanc ES, Cauley JA, Rossouw JE.

Osteoporos Int. 2013 Feb;24(2):567-80. doi: 10.1007/s00198-012-2224-2. Epub 2012 Dec 4.

PMID:
23208074
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Borgström F, Ström O, Kleman M, McCloskey E, Johansson H, Odén A, Kanis JA.

Osteoporos Int. 2011 Mar;22(3):955-65. doi: 10.1007/s00198-010-1291-5. Epub 2010 Jun 8.

PMID:
20532482
[PubMed - indexed for MEDLINE]
19.

Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.

Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R.

Osteoporos Int. 2012 Nov;23(11):2579-89. doi: 10.1007/s00198-011-1869-6. Epub 2012 Jan 6.

PMID:
22222755
[PubMed - indexed for MEDLINE]
20.

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden.

Willis MS.

Int J Technol Assess Health Care. 2002 Fall;18(4):791-807.

PMID:
12602080
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk